CD5 and lymphoma: The feasibility and safety of CAR-T cells targeting other targets including CD1a (NCT05745181, NCT05679895), CD4 (NCT04162340, NCT03829540), CD5 (NCT04594135, NCT03081910), TRBC1 (NCT04828174), CD56 (NCT05941156) and CD37 (NCT04136275) were also evaluated in clinical studies for R/R T-cell leukemia/lymphoma.